financetom
Business
financetom
/
Business
/
Religare arm Care Health Insurance gets thumbs up from its largest shareholder Kedaara Capital
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Religare arm Care Health Insurance gets thumbs up from its largest shareholder Kedaara Capital
Nov 27, 2023 9:42 AM

In a show of confidence and support for Care Health Insurance, Kedaara Capital, the largest shareholder of the insurance company, on Monday (November 27) expressed its backing for the current management and affirmed its support for the decisions made by the board.

Share Market Live

NSE

Sunish Sharma, Founder and Managing Partner of Kedaara Capital, issued a statement commending Care Health Insurance for maintaining the highest standards of governance, compliance, and operational excellence.

He highlighted the company's best-in-class management team and emphasised the pivotal role played by the robust board in guiding the company. Care Health Insurance Ltd (CARE) is a subsidiary of Religare Enterprises Ltd (REL).

"Kedaara is a proud shareholder of Care Health Insurance. Led by a best-in-class management team and guided by a strong board, the company has always had the highest standards of governance, compliance and operational excellence. We look forward to continuing to support it as it goes from strength to strength," Sharma said.

Also Read: Mark Mobius says Gen Z is the big reason why companies globally are rushing to India

This comes after proxy advisory firm InGovern Research raised a red flag against Religare Enterprises alleging the "vested interest" of its chairman Rashmi Saluja due to excessive remuneration as well as regulatory breaches.

In the last 3-4 years, the total valuation of the options of Religare Enterprises Ltd and its subsidiary Care Health Insurance to Saluja is over Rs 480 crore, which is in addition to the compensation paid at REL, according to a report from InGovern.

Shares of CARE were issued to Saluja through ESOPs, despite rejection from the Insurance Regulatory and Development Authority of India (IRDAI) — further, no approval was taken for that from the shareholders of REL, said InGovern in its report. Moreover, there was "no disclosure of CARE ESOPs in REL annual report as part of Saluja’s compensation," it added.

Refuting the charges, Care Health Insurance Independent Director Pratap Venugopal said, "ESOPs were granted to Rashmi Saluja only in her capacity as employee/executive director and chairperson of REL. The ESOPs were not to be granted to her in her capacity as non-executive chairperson of Care Health Insurance."

The IRDAI (Remuneration of Non-Executive Directors of Private Sector Insurers) Guidelines 2016 do not require any permission from the authority for the grant of the specified ESOPs to Rashmi Saluja since the remuneration to the chairman of the board can be decided by the board of directors, he said.

Also Read: Sebi cuts minimum issue size on Social Stock Exchanges by 50%

A total of 1.05 crore options of REL have been granted to Saluja since her appointment in February 2020 as executive chairperson of the financial services holding company, which is valued at over ₹230 crore at present. While CARE, where Saluja is a non-executive chairperson has "excessive grants of stock options," which are valued at over ₹250 crore, the InGovern report added.

Earlier, the Burman family, which has made an open offer for REL, approached the Securities Exchange Board of India (SEBI) through its entities, seeking a probe into the sale of shares by Saluja on September 20, 2023, when they informed about the open offer.

Religare, however, refuted the allegation of Saluja selling shares after being made aware of the open offer, saying the chairperson had sold ESOPs after a long process that was triggered several days prior to the September 20 meeting. Burman family entities, which now collectively hold 21.24% of REL, have written to the SEBI regarding this also.

The Burman family, a promoter of Dabur India and other entities such as Eveready Industries, through its entities, had in September announced a ₹2,116-crore open offer to the shareholders of REL to acquire up to 26% stake in the company. Earlier, the independent directors of the REL raised red flags alleging fraud and other breaches by Burman family entities.

(Edited by : Shoma Bhattacharjee)

First Published:Nov 27, 2023 6:42 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved